Patents and Recent Innovations in Topical Membrane Therapy of Refractory Rhinosinusitis

Author(s): Alan H. Shikani , Konstantinos G. Kourelis .

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 9 , Issue 2 , 2015

Become EABM
Become Reviewer


Chronic Rhinosinusitis (CRS), one of the commonest chronic inflammatory disorders, is encountered daily in all healthcare settings. In its refractory form, CRS seems to prevail over most up-to-date surgical interventions and systemic medical remedies, owing to our poor understanding of its perplexing pathophysiology. Although several systemic influences impinge on the progression of inflammation, the true interplay between offensive and defensive factors takes place on-site, i.e. across the sinonasal epithelial coating. Therefore, current treatment strategies shift the weight of CRS management toward topical modalities, which combine the benefits of surgical approach with the healing effect of conventional medications. An explosive emergence of relevant patents is still in progress, emphasizing the need for classification and comparison. Novel delivery methods of medications into the sinus cavities include modifications of traditional rinses, state-of-the-art nebulizing devices, and the revolutionary concept of sustained drug application utilizing carrier gels or nasal implants. As far as the introduction of new medications is concerned, recent patents propose alterations to the physical and chemical properties of irrigating solutions, as well as the local use of antiseptics, hydragogues, and anti-biofilm agents. This review focuses on the local pathophysiologic events of CRS and the most exciting innovations regarding its topical management.

Keywords: Antimicrobials, biofilms, corticosteroids, patents, refractory chronic rhinosinusitis, rhinotopic therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [86 - 101]
Pages: 16
DOI: 10.2174/1872213X09666150531174219
Price: $58

Article Metrics

PDF: 24